FibroGen Stock Collapses After Its Latest-Stage Drug Faces Another Delay

FibroGen Stock Collapses After Its Latest-Stage Drug Faces Another Delay
ALLISON GATLIN
·2 min read

FibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday.